BofA Cuts Teladoc Target to $7, Goldman Lowers to $8 After User Declines
BofA cut Teladoc’s price target from $7.50 to $7, citing an 18.7% year-over-year drop in BetterHelp monthly users, while Goldman trimmed its target from $9 to $8 after sector stock declines. Teladoc plans to report Q4 metrics as the emotional counseling market is forecast to reach $21.21 billion by 2030.
1. Price Target Cuts
BofA reduced its Teladoc price target from $7.50 to $7, highlighting an 18.7% year-over-year decline in BetterHelp monthly active users and flat quarterly growth while maintaining a Neutral rating. Goldman Sachs followed by cutting its target from $9 to $8 and reaffirmed its Buy rating after observing broad MedTech and Healthcare IT stock declines unrelated to fundamentals.
2. Q4 Earnings Preview
Teladoc is set to release fourth-quarter metrics this week, with analysts focusing on key indicators beyond revenue and EPS such as membership growth, utilization rates in core segments, and engagement trends on BetterHelp. Detailed metric guidance will be critical for investors assessing the company’s execution and growth trajectory following recent analyst adjustments.
3. Market Forecast
The emotional counseling service market is projected to expand from $4.72 billion in 2025 to $21.21 billion by 2030 at a 35% CAGR, driven by rising digital therapy adoption, increased mental health infrastructure investment, and expanded employer-sponsored programs. Major providers including Teladoc Health, Cleveland Clinic, LifeStance, GoodRx, and Headspace are leveraging AI-enabled tele-counseling platforms to enhance accessibility and personalized care.